Doing it our way now: the approach this company pioneered is becoming the market's way
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes that its way of doing things is being adopted by others. Look for statements about others following, copying, or converging on Quanterix's approach. The transcript mentions that at CTAD, there were presentations on blood-based biomarkers, and Quanterix's Simoa platform is used. But does management say others are adopting their approach? They mention that the NIAAA guidelines now define criteria for blood-based biomarkers, and that P-tau217 is the only plasma biomarker appropriate for diagnosing amyloid pathology. This could be seen as the industry moving toward their approach. However, management does not explicitly say competitors are copying them. They say "we believe we're in a strong position to capitalize" and "we're in a great position to maintain a long-term leadership role." That's more about their own position. They also mention that "it will be multiple neuro blood biomarkers measured together" which is a prediction. The key is whether management describes others adopting their specific technology or method. They mention that Lilly presented data using Simoa platform, but that's a partner, not a competitor adopting. They also mention J&J agreement. But no statement about competitors following. The question asks: "does management describe that the WAY THIS COMPANY DOES THINGS ... is NOW BEING ADOPTED, COPIED, OR MOVED TOWARD BY OTHERS IN ITS MARKET?" I don't see explicit evidence. Management talks about their own leadership and the importance of their technology, but not about others copying. They mention that the NIAAA guidelines now define criteria, but that's a regulatory/guideline body, not competitors. They say "This validates the use of fluid based biomarkers" but that's about the field, not specifically their method. They also say "we're in a strong position" but that's not about others following. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| USFD | US Foods Holding Corp. | Q1 2018 | 2018-05-12 | C |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
AES · Q1 2024 → YESThe question is: Does management describe that the WAY THIS COMPANY DOES THINGS is NOW BEING ADOPTED, COPIED, OR MOVED TOWARD BY OTHERS IN ITS MARKET, so that the company's own way of doing things is ...
GGR · Q1 2023 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?
TGT · Q4 2022 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?